Faculty

Institution

Unit

Venue

Andrew Kraft

Professor Emeritus

University of Arizona

Andrew Kraft is currently serving as a Professor Emeritus at University of Arizona.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Andrew Kraft

University of Arizona

Professor Emeritus

You can click a keyword to filter the displayed items

molecular biology oncology cell biology cell signaling tumor biology cancer research biochemistry immunology medicinal research cancer biology enzyme inhibition signal transduction gene expression oncogenes cancer cells cell regulation cancer treatment molecular cancer leukemia protein phosphorylation biological chemistry molecular regulation receptors vascular biology molecular and cellular biology protein science molecular cell biology cellular therapy cell death cancer discovery apoptosis tumor targeting pharmacotherapy transcription regulation tumor suppressors redox biology cancer genetics receptor tyrosine kinases gene regulation anti-cancer agents granulocyte signaling pathways cancer growth novel therapies protein expression inhibitory activity hematological malignancies myeloid neoplasia molecular physiology cytokines cellular biology phorbol esters cancer genomics lymphoid neoplasia hemostasis pim kinase inhibitors genitourinary cancers protein function disease progression pim kinase gene function growth hormone hormonal receptor phase ii trial trail-induced apoptosis proteasome inhibitor bortezomib phase ii study cytoplasmic domain granulocyte-macrophage colony-stimulating factor c-jun expression mitogen-activated protein pim kinases vivo administration phospholipid-dependent protein kinase plasma membrane mitogen-activated protein kinase signal transduction pathways prostate cancer prostatic disease genetic biomarkers tumor growth urology

Notable Scholarly Works

Notable Federal Grants

Collaborators

An Xbp1S–Pim-2 Positive Feedback Loop Controls Il-15–Mediated Survival of Natural Killer Cells. Science Immunology (2023)

Shoubao MaJingjing HanZhenlong LiSai XiaoJianying ZhangJiazhuo YanTingting TangTasha BarrAndrew S. KraftMichael A. CaligiuriJianhua Yu

immune responsesadaptive immune systemcell signalingimmunologynatural killer cells

Data From Mechanisms Behind Resistance to Pi3K Inhibitor Treatment Induced by the Pim Kinase. (2023)

Jin H. SongNeha SinghLibia A. LuevanoSathish K.R. PadiKoichi OkumuraVirginie OliveStephen M. BlackNoel A. WarfelDavid W. GoodrichAndrew S. Kraft

induced resistancedrug resistancecell biologyprotein scienceneurosciencetherapeutic targetspeptide sciencetumor biologyinhibitor treatmenttreatment effectsoncologymedicinal chemistrytherapeutic efficacypharmacotherapyin vitro toxicologymedicinal researchin vivo systemsdermatologypim kinasetreatment development

Figure S6 From Hypoxia-Inducible Pim Kinase Expression Promotes Resistance to Antiangiogenic Agents. (2023)

Andrea L. CasillasRachel K. TothAlva G. SainzNeha SinghAnkit A. DesaiAndrew S. KraftNoel A. Warfel

molecular biologydrug resistanceantiangiogenic agentshypoxia (medicine)

Pim1 Phosphorylates Abi2 to Enhance Actin Dynamics and Promote Tumor Invasion. The Journal of Cell Biology (2023)

Corbin C. JensenAmber N. ClementsHope LiouLauren E. BallJennifer R. BethardPaul R. LanglaisRachel K. TothShailender S. ChauhanAndrea L. CasillasSohail R. DaulatAndrew S. KraftAnne E. CressCindy K. MirantiGhassan MouneimneGreg C. RogersNoel A. Warfel

receptorscancer biologycell biologytumor invasionpharmacologytherapeutic targetsgene expressionmolecular physiologytumor biologyactin dynamicsoncogenic agentsystems biologymembrane biologymolecular cancerredox biologyprotein functionmedicinal researchcancer growthcellular biologyenzyme inhibition

Supplemental Figures 1-3 From Pim Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species. (2023)

Noel A. WarfelAlva G. SainzJin H. SongAndrew S. Kraft

hypoxia (medicine)tumor suppressorspim kinase inhibitorsreactive oxygen speciespharmacologyfree radical biologytherapeutic targetscarcinogenesishypoxic tumor cellstumor biologyoncologyoxidative stressreactive nitrogen speciesredox biologybiochemistryredox signalingmedicinal researchcancer cellsmolecular biologyenzyme inhibition

Supplementary Appendix File From Pim Kinase Inhibitors Block the Growth of Primary T-Cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis. (2023)

James T. LimNeha SinghLibia A. LeuvanoValerie S. CalvertEmanuel F. PetricoinDavid T. TeacheyRichard B. LockMegha PadiAndrew S. KraftSathish K.R. Padi

cancer immunotherapynetwork modeling analysishost responsecancer biologydrug resistanceleukemiapim kinase inhibitorspharmacologyfunctional modificationgene expressionstem cell researchbrain tumor researchdrug discoverysupplementary appendix filelymphoid neoplasiaimmunologyspecific resistancemolecular medicinemedicinal researchresistance pathwaysdermatologyenzyme inhibition

Supplementary Methods and Figures S1-S4 From Mechanisms Behind Resistance to Pi3K Inhibitor Treatment Induced by the Pim Kinase. (2023)

Jin H. SongNeha SinghLibia A. LuevanoSathish K.R. PadiKoichi OkumuraVirginie OliveStephen M. BlackNoel A. WarfelDavid W. GoodrichAndrew S. Kraft

receptorsdrug resistancecell signalingkey sitepharmacologypeptide sciencetumor biologyinhibitor treatmentbrain tumor researchtreatment and preventionneurologymolecular cancerintermittently connected deviceimmunologynanomedicinemedicinal researchdrug targetingreceptor tyrosine kinasessupplementary methodsenzyme inhibitionpim kinase

Oer‐073: A Multicenter Phase 2 Study Evaluating the Role of Pazopanib in Angiosarcoma. Cancer (2022)

Julio Alvarenga ThiebaudVinod RaviSamuel LitwinScott M. SchuetzeSujana MovvaMark AgulnikAndrew S. KraftEric D. TetzlaffNeeta SomaiahMargaret von Mehren

cancer treatmentmedicineoncologycancer research

Synthesis of 2-Oxoquinoline Derivatives as Dual Pim and Mtorc Protein Kinase Inhibitors. Medicinal Chemistry Research (2022)

Giri R. GnawaliKoichi OkumuraKarolina PerezRosa GallagherJulia WulfkuhleEmanuel F. PetricoinSathish Kumar Reddy PadiJeremiah BearssZhiyong HeWei WangAndrew S. Kraft

pharmaceutical chemistrychemical synthesismedicinal chemistrydual pimorganic synthesispharmacologydrug discovery

Abstract 2296: Regulation of P-Body Dynamics and Formation in Tumors Through Edc3 Phosphorylation by Pim and Akt. Cancer Research (2021)

Jeremiah BearssSathish K. PadiNeha SinghMarina Cardo-VilaAndrew S. KraftKoichi Okumura

cancer biologycell biologymolecular regulationpharmacologycarcinogenesistumor biologycancer researchoncologycell regulationcancer carep-body dynamicsradiation oncologymolecular cancermedicinal researchstructural biologycancer growthcancer cellsoncogenescancer genetics

1
2
3
4
5
19
10 / page

Andrew Kraft

Professor Emeritus

University of Arizona

Andrew Kraft is currently serving as a Professor Emeritus at University of Arizona.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Andrew Kraft

University of Arizona

Professor Emeritus

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

An Xbp1S–Pim-2 Positive Feedback Loop Controls Il-15–Mediated Survival of Natural Killer Cells. Science Immunology (2023)

Shoubao MaJingjing HanZhenlong LiSai XiaoJianying ZhangJiazhuo YanTingting TangTasha BarrAndrew S. KraftMichael A. CaligiuriJianhua Yu

immune responsesadaptive immune systemcell signalingimmunologynatural killer cells

Data From Mechanisms Behind Resistance to Pi3K Inhibitor Treatment Induced by the Pim Kinase. (2023)

Jin H. SongNeha SinghLibia A. LuevanoSathish K.R. PadiKoichi OkumuraVirginie OliveStephen M. BlackNoel A. WarfelDavid W. GoodrichAndrew S. Kraft

Figure S6 From Hypoxia-Inducible Pim Kinase Expression Promotes Resistance to Antiangiogenic Agents. (2023)

Andrea L. CasillasRachel K. TothAlva G. SainzNeha SinghAnkit A. DesaiAndrew S. KraftNoel A. Warfel

molecular biologydrug resistanceantiangiogenic agentshypoxia (medicine)

Pim1 Phosphorylates Abi2 to Enhance Actin Dynamics and Promote Tumor Invasion. The Journal of Cell Biology (2023)

Supplemental Figures 1-3 From Pim Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species. (2023)

Noel A. WarfelAlva G. SainzJin H. SongAndrew S. Kraft

Supplementary Appendix File From Pim Kinase Inhibitors Block the Growth of Primary T-Cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis. (2023)

James T. LimNeha SinghLibia A. LeuvanoValerie S. CalvertEmanuel F. PetricoinDavid T. TeacheyRichard B. LockMegha PadiAndrew S. KraftSathish K.R. Padi

Supplementary Methods and Figures S1-S4 From Mechanisms Behind Resistance to Pi3K Inhibitor Treatment Induced by the Pim Kinase. (2023)

Jin H. SongNeha SinghLibia A. LuevanoSathish K.R. PadiKoichi OkumuraVirginie OliveStephen M. BlackNoel A. WarfelDavid W. GoodrichAndrew S. Kraft

Oer‐073: A Multicenter Phase 2 Study Evaluating the Role of Pazopanib in Angiosarcoma. Cancer (2022)

Julio Alvarenga ThiebaudVinod RaviSamuel LitwinScott M. SchuetzeSujana MovvaMark AgulnikAndrew S. KraftEric D. TetzlaffNeeta SomaiahMargaret von Mehren

cancer treatmentmedicineoncologycancer research

Synthesis of 2-Oxoquinoline Derivatives as Dual Pim and Mtorc Protein Kinase Inhibitors. Medicinal Chemistry Research (2022)

Giri R. GnawaliKoichi OkumuraKarolina PerezRosa GallagherJulia WulfkuhleEmanuel F. PetricoinSathish Kumar Reddy PadiJeremiah BearssZhiyong HeWei WangAndrew S. Kraft

pharmaceutical chemistrychemical synthesismedicinal chemistrydual pimorganic synthesispharmacologydrug discovery

Abstract 2296: Regulation of P-Body Dynamics and Formation in Tumors Through Edc3 Phosphorylation by Pim and Akt. Cancer Research (2021)

Jeremiah BearssSathish K. PadiNeha SinghMarina Cardo-VilaAndrew S. KraftKoichi Okumura

1
2
3
4
5
19
10 / page

Similar Faculty Members

Ann Richmond, Ph.D

Institution

Vanderbilt University

immunology

molecular cancer

Devanand Sarkar

Institution

Virginia Commonwealth University

oncology

cancer research

Said M. Sebti

Institution

Virginia Commonwealth University

receptor tyrosine kinase

molecular cancer

Rafael Fridman

Institution

Wayne State University

proteases

cancer biology

John Koomen

Institution

University of South Florida

proteomics

chemical cleavage mechanisms

Gary Johnson

Institution

University of North Carolina at Chapel Hill

mapk kinase

apoptosis

Stephen D. Nimer

Institution

University of Miami

molecular biology

haematopoiesis

Salvatore Vincent Pizzo

Institution

Duke University

pharmacology

biochemistry

Michael B. Yaffe

Institution

Massachusetts Institute of Technology

immunology

dna damage response

Steven Grant

Institution

Virginia Commonwealth University

pathology

malignant blood disorder

Similar Faculty Members

Ann Richmond, Ph.D

Institution

Vanderbilt University

immunology

molecular cancer

Devanand Sarkar

Institution

Virginia Commonwealth University

oncology

cancer research

Said M. Sebti

Institution

Virginia Commonwealth University

receptor tyrosine kinase

molecular cancer

Rafael Fridman

Institution

Wayne State University

proteases

cancer biology

John Koomen

Institution

University of South Florida

proteomics

chemical cleavage mechanisms

Gary Johnson

Institution

University of North Carolina at Chapel Hill

mapk kinase

apoptosis

Stephen D. Nimer

Institution

University of Miami

molecular biology

haematopoiesis

Salvatore Vincent Pizzo

Institution

Duke University

pharmacology

biochemistry

Michael B. Yaffe

Institution

Massachusetts Institute of Technology

immunology

dna damage response

Steven Grant

Institution

Virginia Commonwealth University

pathology

malignant blood disorder